dexlansoprazole
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
63
Go to page
1
2
3
March 26, 2026
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
(clinicaltrials.gov)
- P2 | N=76 | Active, not recruiting | Sponsor: Takeda | Recruiting ➔ Active, not recruiting
Enrollment closed • Gastrointestinal Disorder • Pediatrics
March 27, 2018
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
(clinicaltrials.gov)
- P2 | N=80 | Suspended | Sponsor: Takeda | Trial completion date: Nov 2018 ➔ Nov 2019 | Trial primary completion date: Nov 2018 ➔ Nov 2019
Trial completion date • Trial primary completion date • Gastrointestinal Disorder • Pediatrics
March 11, 2016
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
(clinicaltrials.gov)
- P2 | N=80 | Suspended | Sponsor: Takeda | Not yet recruiting ➔ Suspended
Trial suspension • Gastrointestinal Disorder • Pediatrics
November 27, 2015
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
(clinicaltrials.gov)
- P2 | N=80 | Not yet recruiting | Sponsor: Takeda
New P2 trial • Gastrointestinal Disorder • Pediatrics
March 08, 2018
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
(clinicaltrials.gov)
- P2 | N=80 | Suspended | Sponsor: Takeda | Trial completion date: Mar 2017 ➔ Jan 2021 | Initiation date: Nov 2015 ➔ Nov 2018 | Trial primary completion date: Jan 2017 ➔ Jan 2021
Trial completion date • Trial initiation date • Trial primary completion date • Gastroenterology • Gastroesophageal Reflux Disease • Pediatrics
March 11, 2016
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
(clinicaltrials.gov)
- P2 | N=80 | Suspended | Sponsor: Takeda | Not yet recruiting ➔ Suspended
Trial suspension • Gastroenterology • Gastroesophageal Reflux Disease • Pediatrics
November 27, 2015
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
(clinicaltrials.gov)
- P2 | N=80 | Not yet recruiting | Sponsor: Takeda
New P2 trial • Gastroenterology • Gastroesophageal Reflux Disease • Pediatrics
November 13, 2024
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
(clinicaltrials.gov)
- P2 | N=70 | Recruiting | Sponsor: Takeda | Trial completion date: Jan 2025 ➔ Oct 2027 | Trial primary completion date: Jan 2025 ➔ Oct 2027
Trial completion date • Trial primary completion date • Gastroenterology • Gastroesophageal Reflux Disease • Pediatrics
August 18, 2023
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
(clinicaltrials.gov)
- P2 | N=76 | Recruiting | Sponsor: Takeda | Not yet recruiting ➔ Recruiting
Enrollment open • Gastrointestinal Disorder • Pediatrics
March 17, 2023
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
(clinicaltrials.gov)
- P2 | N=70 | Recruiting | Sponsor: Takeda | Not yet recruiting ➔ Recruiting
Enrollment open • Gastroenterology • Gastroesophageal Reflux Disease • Pediatrics
August 18, 2021
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
(clinicaltrials.gov)
- P2 | N=80 | Not yet recruiting | Sponsor: Takeda | Trial completion date: Nov 2023 ➔ Jan 2025 | Trial primary completion date: Nov 2023 ➔ Jan 2025
Trial completion date • Trial primary completion date • Gastroenterology • Gastroesophageal Reflux Disease • Pediatrics
August 18, 2021
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
(clinicaltrials.gov)
- P2 | N=80 | Not yet recruiting | Sponsor: Takeda | Trial completion date: Sep 2026 ➔ Nov 2027 | Trial primary completion date: Sep 2026 ➔ Nov 2027
Trial completion date • Trial primary completion date • Gastrointestinal Disorder • Pediatrics
November 26, 2019
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
(clinicaltrials.gov)
- P2 | N=80 | Not yet recruiting | Sponsor: Takeda | Trial completion date: Jan 2021 ➔ Nov 2023 | Trial primary completion date: Jan 2021 ➔ Nov 2023
Trial completion date • Trial primary completion date • Gastroesophageal Reflux Disease • Pediatrics
November 26, 2019
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
(clinicaltrials.gov)
- P2 | N=80 | Not yet recruiting | Sponsor: Takeda | Trial completion date: Nov 2019 ➔ Sep 2026 | Trial primary completion date: Nov 2019 ➔ Sep 2026
Trial completion date • Trial primary completion date • Gastrointestinal Disorder • Pediatrics
November 13, 2025
Alembic receives USFDA approval for Dexlansoprazole delayed-release capsules
(ExpressPharma)
- "The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Dexilant Delayed-Release Capsules, 30 mg and 60 mg, of Takeda Pharmaceuticals USA, Inc. (Takeda). Dexlansoprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: (i) healing of all grades of erosive esophagitis (EE), (ii) maintenance of healed EE and relief of heartburn, and (iii) treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD)."
ANDA • Gastrointestinal Disorder
March 18, 2024
Effect of Dexlansoprazole on Bone Homeostasis
(clinicaltrials.gov)
- P1 | N=115 | Completed | Sponsor: Takeda | N=247 ➔ 115
Enrollment change
February 27, 2024
Devonian Announces that its Subsidiary, Altius, Launches Authorized Generic of Dexlansoprazole (Dexilant) in Canada
(Businesswire)
- "Devonian Health Group Inc...is pleased to announce that its wholly-owned subsidiary, Altius Healthcare Inc. ('Altius'), has launched the first authorized generic of dexlansoprazole (Dexilant) in Canada to treat symptoms of gastroesophageal reflux disease (GERD)....Altius’ authorized generic dexlansoprazole is now available in pharmacies for patients across Canada."
Generic launch • Gastroenterology • Gastrointestinal Disorder
November 29, 2023
BABE: Bioequivalence Study of DelanzoᵀᴹDR 60mg (Dexlansoprazole) Capsule With Dexilant® 60mg (Dexlansoprazole) Capsule in Healthy Pakistani Subjects.
(clinicaltrials.gov)
- P1 | N=60 | Completed | Sponsor: University of Karachi | Recruiting ➔ Completed
Trial completion
January 18, 2023
"@TakedaPharma are they any manufacturer coupons for dexilant 30mg in the new year? If so where can I get one?"
(@EeyoreHMC)
January 12, 2023
Effectiveness of Physiologic Testing in PPI Non-Responders
(clinicaltrials.gov)
- P1 | N=240 | Completed | Sponsor: Northwestern University | Enrolling by invitation ➔ Completed | Trial completion date: Mar 2022 ➔ Jul 2022 | Trial primary completion date: Mar 2022 ➔ Jul 2022
Trial completion • Trial completion date • Trial primary completion date • Gastroenterology • Gastroesophageal Reflux Disease
December 12, 2022
"And DexilANT"
(@BassoonYsu)
September 07, 2022
BABE: Bioequivalence Study of DelanzoᵀᴹDR 60mg (Dexlansoprazole) Capsule With Dexilant® 60mg (Dexlansoprazole) Capsule in Healthy Pakistani Subjects.
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: University of Karachi | Trial completion date: Nov 2021 ➔ Nov 2023 | Trial primary completion date: Oct 2021 ➔ Oct 2023
Trial completion date • Trial primary completion date
July 19, 2022
"@TakedaPharma are there any dexilant manufacturers coupons u could send me?"
(@EeyoreHMC)
May 12, 2022
Addendum: Dexlansoprazole for GERD.
(PubMed, Med Lett Drugs Ther)
- No abstract available
Journal • Gastroesophageal Reflux Disease
March 30, 2022
Comparison tables: H2-receptor antagonists and PPIs.
(PubMed, Med Lett Drugs Ther)
- No abstract available
Journal • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Peptic Ulcer
1 to 25
Of
63
Go to page
1
2
3